1,2-diazabicyclo[5.4.0]undec-7-ene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: 1,2-diazabicyclo[5.4.0]undec-7-ene
• 英文别名: diazabicyclo[5.4.0]undec-7-ene；DBU；diazabicyclo-[5,4,0]-undec-7-ene；diazabicyclo-[5.4.0]-undec-7-ene；Diazabicyclo [5.4.0]undec-7-ene；Diazabicyclo(5.4.0) undec-7-ene；1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: SCZNXLWKYFICFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-diazabicyclo[5.4.0]undec-7-ene 、 5,6-O-isopropylidene-L-ascorbic acid 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Tuning of the Thermochemical and Kinetic Properties of Ascorbate by Its Local Environment: Solution Chemistry and Biochemical Implications

  摘要：

  Ascorbate (vitamin C) is a ubiquitous biological cofactor. While its aqueous solution chemistry has long been studied, many in vivo reactions of ascorbate occur in enzyme active sites or at membrane interfaces, which have varying local environments. This report shows that the rate and driving force of oxidations of two ascorbate derivatives by the TEMPO radical (2,2',6,6'-tetramethylpiperidin-1-oxyl) in acetonitrile are very sensitive to the presence of various additives. These reactions proceed by the transfer of a proton and an electron (a hydrogen atom), as is typical of biological ascorbate reactions. The measured rate and equilibrium constants vary substantially with added water or other polar solutes in acetonitrile solutions, indicating large shifts in the reducing power of ascorbate. The correlation of rate and equilibrium constants indicates that this effect has a thermochennical origin rather than being a purely kinetic effect. This contrasts with previous examples of solvent effects on hydrogen atom transfer reactions. Potential biological implications of this apparently unique effect are discussed.

  DOI：

  10.1021/ja102337n
• 作为试剂：
  描述：

  5,5-dimethoxypentanoic acid 2,2-di-tert-butyl-8-hydroxy-6-methyl-6-(2-methylallyl)-hexahydro-1,3,5-trioxa-2-sila-naphthalen-7-yl ester 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 lead(II) chloride 吡啶 、 四丙基高钌酸铵 、 1,2-diazabicyclo[5.4.0]undec-7-ene 、 偶氮二异丁腈 、 四甲基乙二胺 、 4 A molecular sieve 、 三正丁基氢锡 、 二甲基二环氧乙烷 、 4-甲基苯磺酸吡啶 、 四氯化钛 、 sodium hydride 、 N-甲基吗啉氧化物 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯苯 、 丙酮 、 甲苯 、 苯 为溶剂， 反应 102.0h， 生成 8-allyl-2,2-di-tert-butyl-5a,6a-dimethyl-dodecahydro-1,3,5,7,12-pentaoxa-2-silacyclohepta[b]anthracen-9-ol
  参考文献：
  名称：

  Synthesis of an A−E Gambieric Acid Subunit with Use of a C-Glycoside Centered Strategy

  摘要：

  This paper describes our synthesis of the A-E subunit of gambieric acid (GA) in addition to the synthesis of the A-ring and the C-E tricycle. The use of an enol ether-olefin RCM strategy to couple the A and C-E subunits and, in the process, generate the B-ring is noteworthy.

  DOI：

  10.1021/ol0707970

文献信息

• [EN] OXOPIPERAZINE HELIX MIMETICS AS INHIBITORS OF THE p53-MDM2 INTERACTION<br/>[FR] MIMÉTIQUES D'HÉLICE OXOPIPÉRAZINE EN TANT QU'INHIBITEURS DE L'INTERACTION P53-MDM2
  申请人：UNIV NEW YORK

  公开号：WO2015160914A1

  公开（公告）日：2015-10-22

  The present invention relates to oligooxopiperzines for modulating the p53-Mdm2 interaction. Methods of using the oligooxopiperazines are also disclosed.

  本发明涉及用于调节p53-Mdm2相互作用的寡氧哌嗪。还公开了使用寡氧哌嗪的方法。
• CHROMENONE DERIVATIVES
  申请人：BARLAAM Bernard Christophe

  公开号：US20110098271A1

  公开（公告）日：2011-04-28

  The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , n and R 9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  这项发明涉及公式I的香豆素衍生物或其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、n和R9中的每一个具有在描述中定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱的药物的药物中的使用。
• Triazole oxime derivatives having antimycotic acitivity
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0670315A1

  公开（公告）日：1995-09-06

  Triazole oxime derivatives represented by the formula (I): (where Ar is a phenyl group substituted by 1 or 2 halogen atoms; R¹ and R² are typically such that, when taken together with the adjacent carbon atom, they form a cyclopropylidene group; R³ is a straight-chained, branched or cyclic alkyl group having 1 - 4 carbon atoms; R⁴ is typically an optionally substituted straight-chained or branched alkyl group having 1 - 4 carbon atoms; and the wavy line represents either an E- or Z-type bond) or salts thereof. The triazole derivatives exhibit a marked therapeutic effects not only in in vitro experiments but also in in vivo experiments using laboratory animal models such as Aspergillus infected mice. The derivatives are also safe to use. Therefore, they are extremely useful as therapeutics for various superficial dermatomycoses, deep dermatomycoses and deep mycoses (mycoses in internal organs).

  Triazole oxime 衍生物的化学式（I）表示为： （其中 Ar 是一个被 1 或 2 个卤素原子取代的苯基；R¹ 和 R² 通常是这样的，当与相邻的碳原子一起时，它们形成一个环丙烯基团；R³ 是一个直链、支链或环状的含有 1 - 4 个碳原子的烷基团；R⁴ 通常是一个可选择取代的直链或支链烷基团，含有 1 - 4 个碳原子；波浪线代表 E- 或 Z- 类型键）或其盐。这些三唑衍生物不仅在体外实验中表现出显著的治疗效果，而且在使用实验动物模型（如感染曲霉的小鼠）进行体内实验时也表现出显著的治疗效果。这些衍生物也是安全的。因此，它们在治疗各种浅表真菌病、深部真菌病和深部真菌病（内脏器官真菌病）方面非常有用。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。